↑ トップへ　← 戻る

86. 肺動脈性肺高血圧症
［臨床試験数：1,083，薬物数：667（DrugBank：122），標的遺伝子数：98，標的パスウェイ数：185］

Searched query = "Pulmonary arterial hypertension", "PAH", "IPAH", "HPAH", "Eisenmenger syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
6 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2008-007455-26-AT
(EUCTR)		21/01/201010/03/2009A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects with Pulmonary Arterial HypertensionA Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects with Pulmonary Arterial Hypertension Pulmonary hypertension (PH) is a serious and life-threatening disease of the pulmonary vasculature, characterized by profound vasoconstriction and an abnormal proliferation of smooth muscle cells in the walls of the pulmonary arteries.
MedDRA version: 13.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders		Product Name: Cicletanine hydrochloride
Product Code: NA
Product Name: Cicletanine hydrochloride
Product Code: NA		Gilead Sciences, Inc.NULLNot RecruitingFemale: yes
Male: yes		160Phase 2United Kingdom;Germany;Belgium;Spain;Austria
2EUCTR2008-007455-26-GB
(EUCTR)		31/12/200914/04/2009A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects with Pulmonary Arterial HypertensionA Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects with Pulmonary Arterial Hypertension Pulmonary hypertension (PH) is a serious and life-threatening disease of the pulmonary vasculature, characterized by profound vasoconstriction and an abnormal proliferation of smooth muscle cells in the walls of the pulmonary arteries.
MedDRA version: 13.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders		Product Name: Cicletanine hydrochloride
Product Code: Not applicable
Product Name: Cicletanine hydrochloride
Product Code: Not applicable		Gilead Sciences, Inc.NULLNot RecruitingFemale: yes
Male: yes		160Phase 2Spain;Belgium;Austria;Germany;United Kingdom
3EUCTR2008-007455-26-ES
(EUCTR)		28/09/200923/04/2009A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects with Pulmonary Arterial HypertensionEstudio en fase II , de asignación aleatoria, doblemente ciego, controlado con placebo y multicéntrico. Estudio de búsqueda de dosis con cicletanina en sujetos con hipertensión arterial pulmonarA Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects with Pulmonary Arterial HypertensionEstudio en fase II , de asignación aleatoria, doblemente ciego, controlado con placebo y multicéntrico. Estudio de búsqueda de dosis con cicletanina en sujetos con hipertensión arterial pulmonar Pulmonary hypertension (PH) is a serious and life-threatening disease of the pulmonary vasculature, characterized by profound vasoconstriction and an abnormal proliferation of smooth muscle cells in the walls of the pulmonary arteries.La hipertensión pulmonar (PH) es una enfermedad grave y potencialmente mortal de la vasculatura pulmonar, caracterizada por una vasoconstricción profunda y una proliferación anómala de células musculares lisas en las paredes de las arterías pulmonares
MedDRA version: 9.1;Level: LLT;Classification code 10064911;Term: Pulmonary arterial hypertension		Product Name: Cicletanine hydrochloride
Product Name: Cicletanine hydrochloride		Gilead Sciences, Inc.NULLNot RecruitingFemale: yes
Male: yes		160Phase 2United Kingdom;Germany;Belgium;Spain;Austria
4EUCTR2008-007455-26-DE
(EUCTR)		13/08/200923/03/2009Cicletanine Phase II for Pulmonary Arterial HypertensionA Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects with Pulmonary Arterial Hypertension Pulmonary hypertension (PH) is a serious and life-threatening disease of the pulmonary vasculature, characterized by profound vasoconstriction and an abnormal proliferation of smooth muscle cells in the walls of the pulmonary arteries.
MedDRA version: 13.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]		Product Name: Cicletanine hydrochloride
Product Name: Cicletanine hydrochloride		Gilead Sciences, Inc.NULLNot RecruitingFemale: yes
Male: yes		160Phase 2United States;Mexico;Canada;Spain;Belgium;Austria;Australia;Israel;Germany;United Kingdom
5EUCTR2008-007455-26-BE
(EUCTR)		08/06/200930/03/2009A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects with Pulmonary Arterial HypertensionA Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects with Pulmonary Arterial Hypertension Pulmonary hypertension (PH) is a serious and life-threatening disease of the pulmonary vasculature, characterized by profound vasoconstriction and an abnormal proliferation of smooth muscle cells in the walls of the pulmonary arteries.
MedDRA version: 13.1;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders		Product Name: Cicletanine hydrochloride
Product Name: Cicletanine hydrochloride		Gilead Sciences, Inc.NULLNot RecruitingFemale: yes
Male: yes		160Phase 2Spain;Belgium;Austria;Germany;United Kingdom
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6NCT00832507
(ClinicalTrials.gov)		January 200929/1/2009Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial HypertensionPulmonary Arterial HypertensionDrug: Cicletanine;Drug: Cicletanine PlaceboGilead SciencesNULLTerminated16 Years70 YearsBoth162Phase 2United States;Australia;Austria;Belgium;Canada;Germany;Israel;Mexico;Spain;United Kingdom

先頭へ